Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.63 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.63 |
| ▸ | CNR1 | P21554 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001999 | 0.84 | SLC6A9 (0.63) | SLC6A9SLC6A5CNR1CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2010289 | 0.83 | SLC6A9 (0.62) | SLC6A9SLC6A5CNR1CYP2D6CYP2C9 | |
| SCHEMBL3963341 | 0.79 | SLC6A9 (0.58) | SLC6A9SLC6A5CNR1CYP2D6CYP2C9 | |
| SCHEMBL18010560 | 0.78 | LMNA (0.70) | SLC6A9SLC6A5CNR1CNR2KMT2A | |
| SCHEMBL12572421 | 0.78 | SLC6A9 (1.00) | SLC6A9SLC6A5CYP2D6CYP2C9 | |
| SCHEMBL2009331 | 0.78 | SLC6A9 (1.00) | SLC6A9SLC6A5CYP2D6CYP2C9 | |
| SCHEMBL2010557 | 0.78 | SLC6A9 (1.00) | SLC6A9SLC6A5CYP2D6CYP2C9KMT2A | |
| SCHEMBL2009334 | 0.78 | SLC6A9 (1.00) | SLC6A9SLC6A5CYP2D6CYP2C9 | |
| SCHEMBL14678494 | 0.78 | SLC6A9 (0.59) | SLC6A9SLC6A5CNR1CYP2D6CYP2C9 | |
| SCHEMBL14676131 | 0.78 | SLC6A9 (0.70) | SLC6A9SLC6A5CNR1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | SLC6A9 1944/4885SLC6A5 1313/4885CNR1 4451/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | SLC6A9 4478/4885SLC6A5 4075/4885CNR1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.